There are 6 categories that will be vaccinated as a priority in the second phase of the anti-Covid vaccination campaign.
The first will be that of
"extremely vulnerable" subjects
for particular pathologies, regardless of age.
The update of the national vaccination plan for SarsCov2 provides for this.
The 'extremely vulnerable' subjects are those with diseases assessed as "particularly critical as they are related to the death rate associated with Covid-19".
These are
subjects with respiratory, cardiovascular, neurological conditions and disabilities, diabetes and severe endocrinopathies, cystic fibrosis, renal pathology, autoimmune diseases, hepatic and cerebrovascular diseases, oncological pathology, Down syndrome, solid organ transplantation, severe obesity.
The update of the anti-Covid vaccination plan provides for this.
This is followed by people between 75 and 79 years old;
between 70 and 74 years;
people with particular clinical risk from 16 to 69 years;
people between 55 and 69 years without conditions that increase clinical risk;
people between 18 and 54 years without increased clinical risk.
MRna vaccines will go to the first 5 categories, AstraZeneca to the sixth.
In the update of the National Vaccination Plan for SarsCov2 - which Ansa was able to view - the priorities for the second phase of the campaign are indicated
also in relation to the available vaccines.
The document updating the categories and the order of priority for vaccination ('Priority for the implementation of the second phase of the national vaccine plan covid-19') was prepared by the Ministry of Health in collaboration with Aifa, Iss and Agenas, taking into account the reduction of vaccines available in the first phase of the immunization campaign.
The document was subject to discussion with the National Bioethics Committee.
It will now be discussed in the State-Regions Conference.